Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...

The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...

India's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...

Indian drug makers are launching affordable generic Semaglutide, the active ingredient in popular weight-loss drugs. Sun Pharma, Lupin, and...

Novo Nordisk's weight-loss drug patents have expired in India. Several generic companies have launched their versions, increasing competiti...

India's GLP-1 market is set for a massive boom. Following patent expiry, generic versions of semaglutide are launching at significantly low...

Alkem Labs anticipates its upcoming semaglutide launch will drive a strategic shift from acute treatments to chronic care, including diabet...

Indian pharmaceutical stocks, including Lupin, Shilpa Medicare, and Natco Pharma, are under scrutiny following recent USFDA inspections at ...

The data was sourced from BSE at 2.50 pm, and the updates from the real-time data could come with a lag. The below data also pertains only ...

The pharma company is expected to outperform the Indian Pharmaceutical market (IPM) by 1.5 times growth rate for the next 2 years.

A rise in margins in the coming years, improved domestic business, leadership position in some segments, and the correction in its stock pr...

Alkem is bringing in a fresh brand. Evogliptin has been approved in South Korea and the company is waiting for an approval from the USFDA a...

On Dr Lal PathLabs, Bansal said valuation of the company appears expensive after the strong listing and investors should wait for the compa...

People used to buy pharma stocks for the overseas business, but with the regulatory issues, it is getting tougher now.

With many unlisted cos in sector, chances of them tapping mkt looks high: Nomura Fin's Oza.

Among the 10 products that have been mentioned in the proposal are Sun Pharma's multi-vitamin capsule 'Revital', Pfizer's 'Ferradol' and Al...

80% of the company's revenues currently come from domestic operations and now it's main focus is on the US market.